A first-in-class pill called Sotyktu, developed by BMS, has received FDA approval to treat psoriatic arthritis. The approval of Sotyktu is noted, although other recent FDA activities and pharmaceutical industry trends are also being discussed. The context of this approval among other pharmaceutical developments is being considered.